Sarkis Barrett Kalindjian

Title: **Sarkis Barrett Kalindjian: Innovator in Therapeutic Compounds**

Introduction

Sarkis Barrett Kalindjian is a notable inventor based in Bansted, Great Britain. With two patents to his name, Kalindjian has made significant contributions to the field of therapeutic compounds, particularly focusing on advancements in neurological treatments.

Latest Patents

Kalindjian's latest inventions include innovative crystalline forms of 4-(5-(4,7-dimethylbenzofuran-2-yl)-1,2,4-oxadiazol-3-yl)benzoic acid, also known as 'BHBA-001.' This invention, which acts as a selective retinoic acid receptor beta (RARβ) agonist, plays a crucial role in promoting neurite development, outgrowth, and regeneration. These compounds hold potential for treating various neurological injuries, such as spinal cord injuries, and represent a significant step forward in therapeutic applications for related medical conditions.

Career Highlights

Kalindjian is affiliated with King's College London, an esteemed institution known for its research and innovation. His work exemplifies the bridge between academic research and practical medical applications, showcasing his commitment to improving patient outcomes through novel therapeutic strategies.

Collaborations

Throughout his career, Sarkis Barrett Kalindjian has collaborated with fellow researchers and inventors, including Ronnie Maxwell Lawrence and Edwin Aret. These collaborations have undoubtedly enriched his research endeavors and contributed to the success of his innovations in therapeutic compounds.

Conclusion

Sarkis Barrett Kalindjian stands out as an inventive force in the realm of therapeutic compounds. His achievements not only highlight his expertise but also underline the importance of innovative research in advancing medical science. As inventions like BHBA-001 continue to emerge, the potential to improve treatments for neurological conditions becomes increasingly promising.